CDH1

Cadherin-1

1,939 patent compounds predicted against CDH1, 1,247 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3469324	1.00	2/20
SCHEMBL6740513	0.40	2/20
SCHEMBL2260791	1.00	1/20
SCHEMBL892967	0.82	1/20
SCHEMBL9953732	0.81	1/20
SCHEMBL1258992	0.74	1/20
SCHEMBL6291531	0.73	1/20
SCHEMBL7262881	0.72	1/20
Cercosporin (SCHEMBL498747)	0.71	1/20
Cercosporin (SCHEMBL6305985)	0.71	1/20
SCHEMBL1458816	0.68	1/20
SCHEMBL892240	0.67	1/20
SCHEMBL6227154	0.67	1/20
SCHEMBL11621542	0.67	1/20
SCHEMBL11623030	0.67	1/20
SCHEMBL6275897	0.65	1/20
SCHEMBL7269138	0.65	1/20
SCHEMBL10643646	0.65	1/20
Hydrochloric Acid (SCHEMBL8591571)	0.63	1/20
SCHEMBL5696651	0.62	1/20

Germline variants in CDH1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDH1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDH1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Identifying Predictors Of Response To Mepolizumab In CRSwNP	PHASE4	RECRUITING
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)	PHASE2	UNKNOWN
Avutometinib and Defactinib in Diffuse Gastric Cancer	PHASE2	RECRUITING
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer	PHASE2	COMPLETED
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.	PHASE2	WITHDRAWN
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors	PHASE1	UNKNOWN
KRAS Wild-type Metastatic Colorectal Cancer Trial	PHASE1	COMPLETED
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study	nan	COMPLETED
Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues	nan	RECRUITING
Epithelial Mesenchymal Transition Markers in OSMF	nan	COMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.	nan	UNKNOWN
Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial	nan	NOT_YET_RECRUITING
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis	nan	COMPLETED
CDH1 Germline Mutations in Lobular Breast Cancer	nan	COMPLETED
Influence of EMT on CTCs and Disease Progression in Prostate Cancer	nan	COMPLETED
CDH1-associated Blepharocheilodontic Syndrome Registry	nan	RECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry	nan	ACTIVE_NOT_RECRUITING
Epithelial Mesenchymal Transition and Periodontitis	nan	UNKNOWN
Early Onset and Familial Gastric Cancer Registry	nan	COMPLETED
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer	nan	COMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA	nan	RECRUITING
Role of Nox2 in CNI-induced Renal Fibrosis	nan	COMPLETED
Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan	nan	UNKNOWN
Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential	nan	UNKNOWN
Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer	nan	RECRUITING
Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CDH1 binder may also engage these)

Protein	Name	Similarity
Q5RAX1	—	1.000	Q5RAX1 →
Q6R8F2	—	1.000	Q6R8F2 →
F1PAA9	—	1.000	F1PAA9 →
Q9R0T4	—	0.998	Q9R0T4 →
P08641	—	0.993	P08641 →
B2KI42	—	0.993	B2KI42 →
P20310	—	0.992	P20310 →
B4USZ0	—	0.992	B4USZ0 →
P19022	—	0.992	P19022 →
P09803	—	0.991	P09803 →
P15116	—	0.990	P15116 →
P19534	—	0.990	P19534 →
P79883	—	0.989	P79883 →
P10288	—	0.989	P10288 →
B0KW95	—	0.988	B0KW95 →
Q9Z1Y3	—	0.987	Q9Z1Y3 →
P10287	—	0.986	P10287 →
Q90275	—	0.986	Q90275 →
P33147	—	0.986	P33147 →
Q5R9X1	—	0.985	Q5R9X1 →
P22223	—	0.985	P22223 →
P19535	—	0.981	P19535 →
P33152	—	0.979	P33152 →
Q90Z37	—	0.973	Q90Z37 →
P33148	—	0.973	P33148 →
P39038	—	0.970	P39038 →
Q6URK6	—	0.965	Q6URK6 →
O02840	—	0.965	O02840 →
P33151	—	0.964	P33151 →
P55283	—	0.963	P55283 →